UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Systemic exposures of gantenerumab: An integrated population pharmacokinetics (popPK) analysis across multiple clinical studies

Alzheimer's & dementia, 2023-12, Vol.19 (S24), p.n/a

2023

Volltextzugriff (PDF)

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial

Ophthalmology (Rochester, Minn.), 2019-08, Vol.126 (8), p.1155

2019

Volltextzugriff (PDF)

Enabling Subcutaneous Dosing of Gantenerumab in Alzheimer’s Disease (S14.006)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial

JAMA ophthalmology, 2020-09, Vol.138 (9), p.955

2020

Volltextzugriff (PDF)

GRADUATE I AND II: Factors that may influence participant response to subcutaneous gantenerumab

Alzheimer's & dementia, 2023-12, Vol.19 (S24), p.n/a

2023

Volltextzugriff (PDF)

A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant Intravenous Microdose Administration of [13C]Tofogliflozin in Humans

Clinical pharmacokinetics, 2013-06, Vol.52 (6), p.463-473

2013

Volltextzugriff (PDF)

Ocular Half-Life of Intravitreal Biologics in Humans and Other Species: Meta-Analysis and Model-Based Prediction

Molecular pharmaceutics, 2020-02, Vol.17 (2), p.695-709, Article acs.molpharmaceut.9b01191

2020

Volltextzugriff (PDF)

Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2)

Hypertension (Dallas, Tex. 1979), 2017-01, Vol.69 (1), p.189-196

2017

Volltextzugriff (PDF)

GRADUATE I and II: Subgroup analysis and correlations of biomarkers

Alzheimer's & dementia, 2023-12, Vol.19 (S24), p.n/a

2023

Volltextzugriff (PDF)

A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration

Molecular pharmaceutics, 2016-09, Vol.13 (9), p.2941-2950

2016

Volltextzugriff (PDF)

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus

Drug research (Stuttgart), 2019-06, Vol.69 (6), p.314-322

2019

Volltextzugriff (PDF)

GRADUATE I AND II: Revisiting the key findings from two Phase III studies evaluating the efficacy and safety of subcutaneous gantenerumab in early Alzheimer’s disease (AD)

Alzheimer's & dementia, 2023-12, Vol.19 (S24), p.n/a

2023

Volltextzugriff (PDF)

Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6-phosphatase system

American journal of physiology: Gastrointestinal and liver physiology, 1998-06, Vol.274 (6), p.G1087-G1093

1998

Volltextzugriff (PDF)

A Baseline Score to Predict Response to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration

Translational vision science & technology, 2021-05, Vol.10 (6), p.11-11

2021

Volltextzugriff (PDF)

Phase I Trial of Anti–Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration

Ophthalmology retina, 2017-11, Vol.1 (6), p.474-485

2017

Volltextzugriff (PDF)

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema

Ophthalmology (Rochester, Minn.), 2019-08, Vol.126 (8), p.1155-1170

2019

Volltextzugriff (PDF)

Comparison of in Vitro P-Glycoprotein Screening Assays: Recommendations for Their Use in Drug Discovery

Journal of medicinal chemistry, 2003-04, Vol.46 (9), p.1716-1725

2003

Volltextzugriff (PDF)

Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans

Xenobiotica, 2014-04, Vol.44 (4), p.369-378

2014

Volltextzugriff (PDF)

Hepatic uptake of synthetic chlorogenic acid derivatives by the organic anion transport proteins

The Journal of pharmacology and experimental therapeutics, 2001-01, Vol.296 (1), p.91

2001

Volltextzugriff (PDF)

Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study

BMJ open ophthalmology, 2017-06, Vol.1 (1), p.e000063-e000063

2017

Volltextzugriff (PDF)

3,4-Dihydro-2H-benzo[1,4]oxazine derivatives as 5-HT sub(6) receptor antagonists

Bioorganic & medicinal chemistry letters, 2007-06, Vol.17 (12), p.3504-3507

2007

Volltextzugriff (PDF)

3,4-Dihydro-2 H-benzo[1,4]oxazine derivatives as 5-HT 6 receptor antagonists

Bioorganic & medicinal chemistry letters, 2007, Vol.17 (12), p.3504-3507

2007

Volltextzugriff (PDF)

Prolonged blood glucose reduction in mrp-2 deficient rats (GY/TR −) by the glucose-6-phosphate translocase inhibitor S 3025

Biochimica et biophysica acta, 2002-01, Vol.1569 (1), p.105-110

2002

Volltextzugriff (PDF)

Heterogeneity in hepatic transport of somatostatin analog octapeptides

Hepatology (Baltimore, Md.), 1994-07, Vol.20 (1), p.191-200

1994

Volltextzugriff (PDF)

Heterogeneity in hepatic transport of somatostatin analog octapeptides

Hepatology (Baltimore, Md.), 1994-07, Vol.20 (1), p.191-200

1994

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(84)

Publikationsform

Sprache

Englisch
(87)
Japanisch
(12)
Deutsch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Systemic exposures of gantenerumab: An integrated population pharmacokinetics (popPK) analysis across multiple clinical studies

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial

Enabling Subcutaneous Dosing of Gantenerumab in Alzheimer’s Disease (S14.006)

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial

GRADUATE I AND II: Factors that may influence participant response to subcutaneous gantenerumab

A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant Intravenous Microdose Administration of [13C]Tofogliflozin in Humans

Ocular Half-Life of Intravitreal Biologics in Humans and Other Species: Meta-Analysis and Model-Based Prediction

Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2)

GRADUATE I and II: Subgroup analysis and correlations of biomarkers

A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus

GRADUATE I AND II: Revisiting the key findings from two Phase III studies evaluating the efficacy and safety of subcutaneous gantenerumab in early Alzheimer’s disease (AD)

Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6-phosphatase system

A Baseline Score to Predict Response to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration

Phase I Trial of Anti–Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema

Comparison of in Vitro P-Glycoprotein Screening Assays: Recommendations for Their Use in Drug Discovery

Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans

Hepatic uptake of synthetic chlorogenic acid derivatives by the organic anion transport proteins

Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study

3,4-Dihydro-2H-benzo[1,4]oxazine derivatives as 5-HT sub(6) receptor antagonists

3,4-Dihydro-2 H-benzo[1,4]oxazine derivatives as 5-HT 6 receptor antagonists

Prolonged blood glucose reduction in mrp-2 deficient rats (GY/TR −) by the glucose-6-phosphate translocase inhibitor S 3025

Heterogeneity in hepatic transport of somatostatin analog octapeptides

Heterogeneity in hepatic transport of somatostatin analog octapeptides

Suchergebnisse filtern